Literature DB >> 25494645

VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription.

Prashant K Singh1, Mark D Long, Sebastiano Battaglia, Qiang Hu, Song Liu, Lara E Sucheston-Campbell, Moray J Campbell.   

Abstract

The Vitamin D Receptor (VDR) is a member of the nuclear receptor superfamily and is of therapeutic interest in cancer and other settings. Regulation of microRNA (miRNA) by the VDR appears to be important to mediate its actions, for example, to control cell growth. To identify if and to what extent VDR-regulated miRNA patterns change in prostate cancer progression, we undertook miRNA microarray analyses in 7 cell models representing non-malignant and malignant prostate cells (RWPE-1, RWPE-2, HPr1, HPr1AR, LNCaP, LNCaP-C4-2, and PC-3). To focus on primary VDR regulatory events, we undertook expression analyses after 30 minutes treatment with 1α,25(OH)2D3. Across all models, 111 miRNAs were significantly modulated by 1α,25(OH)2D3 treatment. Of these, only 5 miRNAs were modulated in more than one cell model, and of these, only 3 miRNAs were modulated in the same direction. The patterns of miRNA regulation, and the networks they targeted, significantly distinguished the different cell types. Integration of 1α,25(OH)2D3-regulated miRNAs with published VDR ChIP-seq data showed significant enrichment of VDR peaks in flanking regions of miRNAs. Furthermore, mRNA and miRNA expression analyses in non-malignant RWPE-1 cells revealed patterns of miRNA and mRNA co-regulation; specifically, 13 significant reciprocal patterns were identified and these patterns were also observed in TCGA prostate cancer data. Lastly, motif search analysis revealed differential motif enrichment within VDR peaks flanking mRNA compared to miRNA genes. Together, this study revealed that miRNAs are rapidly regulated in a highly cell-type specific manner, and are significantly co-integrated with mRNA regulation.

Entities:  

Keywords:  VDR; Vitamin D; epigenetic regulation; microRNA; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 25494645      PMCID: PMC4623602          DOI: 10.4161/15592294.2014.989088

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  78 in total

1.  Open source clustering software.

Authors:  M J L de Hoon; S Imoto; J Nolan; S Miyano
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

2.  Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.

Authors:  Tsg-Hui Chang; Eva Szabo
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

3.  Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease.

Authors:  Luke A Selth; Scott L Townley; Joanna L Gillis; Wayne D Tilley; Lisa M Butler
Journal:  Methods Mol Biol       Date:  2013

4.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 5.  The interplay between transcription factors and microRNAs in genome-scale regulatory networks.

Authors:  Natalia J Martinez; Albertha J M Walhout
Journal:  Bioessays       Date:  2009-04       Impact factor: 4.345

6.  Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer.

Authors:  Katsuki Tsuchiyama; Hideaki Ito; Minekatsu Taga; Seiji Naganuma; Yukinosuke Oshinoya; Ken-Ichi Nagano; Osamu Yokoyama; Hiroshi Itoh
Journal:  Prostate       Date:  2012-11-26       Impact factor: 4.104

7.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences.

Authors:  Jeremy Goecks; Anton Nekrutenko; James Taylor
Journal:  Genome Biol       Date:  2010-08-25       Impact factor: 13.583

8.  A Role for the PPARgamma in Cancer Therapy.

Authors:  Moray J Campbell; Carsten Carlberg; H Phillip Koeffler
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  The microRNA.org resource: targets and expression.

Authors:  Doron Betel; Manda Wilson; Aaron Gabow; Debora S Marks; Chris Sander
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

Review 10.  Nuclear receptors and the Warburg effect in cancer.

Authors:  James L Thorne; Moray J Campbell
Journal:  Int J Cancer       Date:  2014-06-16       Impact factor: 7.396

View more
  6 in total

Review 1.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.

Authors:  Sylvia Christakos; Puneet Dhawan; Annemieke Verstuyf; Lieve Verlinden; Geert Carmeliet
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Pan-cancer analyses of the nuclear receptor superfamily.

Authors:  Mark D Long; Moray J Campbell
Journal:  Nucl Receptor Res       Date:  2015-12-15

Review 3.  Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells.

Authors:  Mariarosaria Negri; Annalisa Gentile; Cristina de Angelis; Tatiana Montò; Roberta Patalano; Annamaria Colao; Rosario Pivonello; Claudia Pivonello
Journal:  Nutrients       Date:  2020-06-17       Impact factor: 5.717

4.  MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.

Authors:  Kyungjin Lee; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2016-09-07       Impact factor: 5.742

Review 5.  Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans.

Authors:  Ken Batai; Adam B Murphy; Larisa Nonn; Rick A Kittles
Journal:  Front Immunol       Date:  2016-02-22       Impact factor: 7.561

Review 6.  The Role of Estrogens and Vitamin D in Cardiomyocyte Protection: A Female Perspective.

Authors:  Clara Crescioli
Journal:  Biomolecules       Date:  2021-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.